The European Commission has begun an investigation into the European pharmaceutical industry. The Co mmission is looking at possible anti-competitive behaviour by pharmaceutical companies that might be having a significant impact on the introduction of new drugs and cheaper generics into the European markets. The investigation is specifically focusing on the dispute settlement practices between the R&D pharmaceutical companies and the generic companies that often result in delay in the introduction of generic medicines and/or increase in prices charged by the R&D based pharmaceutical companies for their products.